Adderall XR: Long acting stimulant for single daily dosing

Expert Review of Neurotherapeutics

Volumn 4, Issue 6, 2004, Pages 927-934

  Sallee, Floyd R ^a   Smirnoff, Alexander V ^a  

^a Department of Psychiatry ^*  (United States)

Author keywords

Adderall; Adderall XR; Attention deficit hyperactivity disorder; SLI381

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; SL 1381; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ANOREXIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ASTHENIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NERVOUSNESS; NEUROPHARMACOLOGY; OPPOSITIONAL DEFIANT DISORDER; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; REVIEW; VOMITING;

ADOLESCENT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DRUG DELIVERY SYSTEMS; FOLLOW-UP STUDIES; HUMANS; TIME FACTORS;

EID: 8344248672     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.6.927     Document Type: Review

References (37)

1. Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention deficit hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch. Intern. Med. 164, 1221-1226 (2004).
2. Pediatrics AAO. Clinical Practice Guideline: treatment of the school-aged child with attention deficit hyperactivity disorder. Pediatrics 108, 1033-1044 (2000).
3. Brown RT, Freeman WS, Perrin JM et al. Prevalence and assessment of attention deficit hyperactivity disorder in primary care settings. Pediatrics 107, E43 (2001).
4. Barkley RA. Attention deficit hyperactivity disorder. Sci. Am. 279, 66-71 (1998).
5. Zarin DA, Tanielian TL, Suarez AP, Marcus SC. Treatment of attention deficit hyperactivity disorder by different physician specialties. Psychiatr. Serv. 49, 171 (1998).
6. Wilens TE, Faraone SV, Biederman J. Attention deficit hyperactivity disorder in adults. JAMA 292, 619-623 (2004).
7. Greenhill BBO. Ritalin: Theory and Practice. Second Edition. Mary Ann Liebert Inc., NY, USA (2000).
8. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry 160, 1909-1918 (2003).
9. Grcevich S. SLI381: along-acting psychostimulant preparation for the treatment of attention deficit hyperactivity disorder. Expert Opin. Investig. Drugs 10, 2003-2011 (2001).
10. Pliszka SR, Greenhill LL, Crismon ML et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention Deficit Hyperactivity Disorder. Part II: Tactics. Attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 39, 920-927 (2000).
11. Hardman JG. Goodman & Gilmans The Pharmacological Basis of Therapeutics. Tenth Edition. McGraw-Hill, OH, USA (2001).
12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention deficit hyperactivity disorder: a review and integration. Behav. Brain. Res. 94, 127-152 (1998).
13. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J. Am. Acad. Child Adolesc. Psychiatry 35, 264-272 (1996).
14. Arnold LE, Wender PH, McCloskey K, Snyder SH. Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch. Gen. Psychiatry 27, 816-822 (1972).
15. Arnold LE, Huestis RD, Smeltzer DJ, Scheib J, Wemmer D, Colner G. Levoamphetamine versus dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch. Gen. Psychiatry 33, 292-301 (1976).
16. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention deficit hyperactivity disorder. Clin. Pharmacokinet. 40, 753-772 (2001).
17. Swanson JM, Wigal S, Greenhill LL et al. Analog classroom assessment of Adderall in children with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 37, 519-526 (1998).
18. McCracken JT, Biederman J, Greenhill LL et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 42, 673-683 (2003). Established the duration of Adderall XR effect as 12 h.
19. McGough JJ, McCracken JT. Assessment of attention deficit hyperactivity disorder: a review of recent literature. Curr. Opin. Pediatr. 12, 319-324 (2000).
20. Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed and sprinkled administration. Pharmacotherapy 22, 1405-1415 (2002).
21. Tulloch S, Frazer N, Kisicki J, Clausen S, Yu K. Dose proportionality of 20, 40, and 60 mg of an extended-release formulation of mixed amphetamine salts in adults. 43rd Annual National Clinical Drug Evaluation, FL, USA (2003).
22. Boellner SW, Tulloch SJ, Zhang Y. A single-dose bioequivalence study comparing 1 X 30 mg capsule of SLI381 to 3 X 10 mg capsules of SLI381 in pediatric subjects. NCDEU 41 Annual Meeting, AZ, USA (2001).
23. McGough JJ, Biederman J, Greenhill LL et al. Pharmacokinetics of SLI381 (Adderall XR), an extended-release formulation of Adderall. J. Am. Acad. Child. Adolesc. Psychiatry 42, 684-691 (2003).
24. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention deficit hyperactivity disorder. Pediatrics 110, 258-266 (2002). Definitive efficacy and safety report of Adderall XR in children with attention deficit hyperactivity disorder.
25. Wigal S, McGough JJ, McCracken JT. Analog classroom study of amphetamine extended release and atomoxetine in youth with ADHD. 157th Annual Meeting of American Psychiatric Association. NY, USA (2004).
26. Sallee FR, Ambrosini PJ, Lopez FA. Health-related quality of life and treatment satisfaction and preference in the community. J. Outcomes. Res. (2004) (In Press).
27. Faraone S, Biederman J, Spencer T. Dose-response efficacy of mixed amphetamine salts XR in adults with ADHD. 157th Annual Meeting of American Psychiatric Association, NY, USA (2004).
28. Weisler JB, Chrisman AK, Wilens TS, Tulloch S. Long-term safety and efficacy of once-daily Adderall XR in adults with ADHD. 16th Annual US Psychiatric and Mental Health Congress, FL, USA (2003).
29. Spencer T, Biederman J, Abikoff H, Pliszka SR, Lopez FA. Safety and efficacy of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder (ODD). 157th Annual Meeting of American Psychiatric Association, NY, USA (2004).
30. Lopez FA, Mays DA, Shi L, Tulloch S. Tolerability of Adderall XR in girls with attention deficit hyperactivity disorder. 16th Annual US Psychiatric and Mental Health Congress, FL, USA (2003).
31. Biederman ST, Faraone S. Extended-release mixed amphetamine salts in ADHD: growth parameter analysis. American Psychiatric Association Annual Meeting, CA, USA (2003).
32. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J. Am. Acad. Child Adolesc. Psychiatry 40, 525-529 (2001).
33. Ambrosini LF, Chandler MC. An open-label community assesment trial of Adderall XR in pediatric ADHD. American Psychiatric Association Annual Meeting, CA, USA (2003).
34. Chandler LF, Biederman J. Long-term Adderall XR treatment improves quality of life in ADHD children. American Psychiatric Association Annual Meeting, CA, USA (2003).
35. Thomas S, Upadhyaya H. Adderall and seizures. J. Am. Acad. Child. Adolesc. Psychiatry 41, 365 (2002).
36. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a meta-analysis. J. Clin. Psychopharmacol. 22, 466-473 (2002).
37. Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention deficit hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113, 206-216 (2004).